Two Sigma Securities LLC Raises Stake in United Therapeutics Corporation $UTHR

Two Sigma Securities LLC lifted its position in United Therapeutics Corporation (NASDAQ:UTHR) by 434.5% in the second quarter, HoldingsChannel.com reports. The firm owned 2,726 shares of the biotechnology company’s stock after purchasing an additional 2,216 shares during the quarter. Two Sigma Securities LLC’s holdings in United Therapeutics were worth $1,477,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of UTHR. Toth Financial Advisory Corp boosted its holdings in United Therapeutics by 2,400.0% in the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock worth $27,000 after buying an additional 48 shares during the period. Fiduciary Financial Advisors purchased a new position in shares of United Therapeutics in the second quarter valued at about $30,000. Entrust Financial LLC purchased a new position in shares of United Therapeutics in the fourth quarter valued at about $31,000. Caitlin John LLC bought a new position in shares of United Therapeutics in the second quarter worth about $37,000. Finally, International Assets Investment Management LLC boosted its stake in shares of United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 64 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $547.61, for a total value of $5,202,295.00. Following the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,185,323.93. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,311,581.28. This trade represents a 34.63% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 414,075 shares of company stock valued at $221,568,985. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Stock Performance

UTHR stock opened at $510.38 on Tuesday. The firm has a fifty day moving average price of $529.90 and a 200 day moving average price of $539.42. United Therapeutics Corporation has a fifty-two week low of $303.08 and a fifty-two week high of $609.35. The firm has a market cap of $21.89 billion, a PE ratio of 18.26, a price-to-earnings-growth ratio of 1.75 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the prior year, the firm earned $6.41 earnings per share. United Therapeutics’s revenue was down 1.9% on a year-over-year basis. On average, equities analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on UTHR shares. Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Bank of America dropped their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.